Single-cell brain study of Alzheimer's disease across regions
Official title: Single cell multiomic characterization of the spectrum of Alzheimer's disease across the brain.
Funded at Allen Institute · NIH-11416730 · Data updated 2026-11-12
A large NIH project will map the cellular and molecular changes in the brains of people with Alzheimer's disease using cutting-edge single-cell genomics.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Allen Institute NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project start | March 1, 2020 |
| Project end | August 31, 2030 |
| Funding year | 2026 |
| Award (this year) | $7,114,170 |
| NIH project number | 5U19AG060909-07 |
| Project ID | NIH-11416730 on NIH RePORTER |
Who could benefit from this research
✓Could help
Individuals with Alzheimer’s disease or related dementias who provide postmortem brain tissue or participate in substudies as part of the SEA-AD2.0 framework.
✕Less likely to help
Participants not contributing Brain tissue or data for the SEA-AD2.0 analyses may not directly benefit.
What this research studies
This project builds on prior work to map how Alzheimer’s disease affects different brain regions and cell types. Researchers will profile gene activity at the single-cell level across multiple brain areas and genetic backgrounds to understand disease progression. The study will combine neuropathology with genomics to identify cell types and pathways that change as AD advances, including subcortical regions that may be affected early. The findings could help pinpoint targets for future therapies and improve our understanding of how AD progresses in diverse populations.
Why it matters
Potential benefit: Better understanding of which brain cells and pathways drive Alzheimer’s progression, potentially guiding more effective treatments in the future.
How similar studies have gone: Earlier SEA-AD work showed meaningful cellular maps; SEA-AD2.0 aims to broaden coverage and generalizability.
Where this research is happening
-
Allen Institute
Seattle, United States Active
Researchers
- Principal investigator: Hodge, Rebecca Dawn — Allen Institute
- Study coordinator: Hodge, Rebecca Dawn
Related research
Other NIH-funded projects on the same topics.
-
Understanding how brain activity changes may drive Alzheimer’s disease progression in a mouse model
Researchers are testing how changes in brain signals and protein cleanup processes affect the development of Alzheimer’s disease in mice.
-
Thiamine-boosting therapy for Alzheimer’s: understanding how benfotiamine may reduce harmful AGE in DP patients
A medication-based approach using high-dose vitamin B1 (benfotiamine) is studied to help people with Alzheimer's by reducing harmful sugar-related molecules.
-
Non-invasive tears biomarker for early Alzheimer's in LMICs
A low-cost, tear-based biomarker approach aims to detect early Alzheimer’s disease in older adults in Peru and similar settings.
-
Turning APOE4 into protective APOE2 or APOE3Christchurch to help with Alzheimer’s
A patient-facing explanation of a treatment idea that aims to change a genetic risk factor for Alzheimer's disease in the brain.
-
Telomerase in Alzheimer’s Disease: how aging biology could influence memory and brain health
Researchers are exploring a new brain-aging mechanism linked to telomerase, with potential to slow or modify Alzheimer’s disease in people and improve cognitive function.
-
Biomarkers of Alzheimer’s Disease: Sensory, Motor, and Cognitive Clues
Researchers are testing simple sensory and movement tasks to find early signs of Alzheimer’s disease so they can diagnose and treat people sooner.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.